Curevo Vaccine Announces $60 Million Series A Financing To Support Clinical Development Of Next Generation Subunit Vaccines
Amount Raised
$60 Million
Round Type
Series A
SeattleBiotechnologyHealthcareMobileSportsPlatformsDescription
Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly-effective vaccines, today announced the closing of a $60 million Series A financing round.
Who else raised in Healthcare and Mobile around the same time
Companies in the same sectors as Curevo that raised within 45 days of this round, from Fundz verified event records.
- Ocelot Bio raised $36M (Series A) on March 23, 2022.
- Spotlight Therapeutics, Inc. raised $37M (Series B) on March 22, 2022.
- Iron Hills Therapeutics, Inc. raised $1.7M (Seed) on March 22, 2022.
- U.S. Renal Care raised $2.8M (Seed) on March 17, 2022.
- Sherlock Biosciences raised $80M on March 15, 2022.
- Ceptur Therapeutics, Inc. raised $21M on March 9, 2022.
Who to call at Curevo, and when
A new round usually means Curevo is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Curevo raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Curevo, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Curevo. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Curevo raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansCurevo raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.